

Product Datasheet

ARS-1630

Catalog No. **BP-01922** · CAS **1698055-86-5** · Form **free base** · Physical state **solid** · Color **white to yellow** · Version **1.0** ·
Revision **2026-09-04**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Ras	Research area Cancer
----------------------	--------------------------------

Molecular formula **C₂₁H₁₇ClF₂N₄O₂**

Molecular weight **430.8350**

STRUCTURE



DESCRIPTION

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.

BIOLOGICAL ACTIVITY

In Vitro

KRASG12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state. This strategy proves feasible for inhibiting mutant KRAS in vitro.

SOLUBILITY

Soluble in DMSO

REFERENCES

- [1]. Liansheng Li, et al. Inhibitors of kras g12c. WO 2015054572 A1.
- [2]. Janes MR, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018 Jan 25;172(3):578-589.e17.